Home » Otsuka Wins Abilify Patent Dispute, Barring Generics Until 2015
Otsuka Wins Abilify Patent Dispute, Barring Generics Until 2015
Japanese drugmaker Otsuka Pharmaceutical has won a major victory against several companies seeking to make generic versions of its blockbuster antipsychotic Abilify after a federal judge upheld a key patent related to the drug’s active ingredient. The court ruled that Otsuka’s ’528 patent covering aripiprazole, Abilify’s active ingredient, is valid and enforceable. As a result, Abilify has patent protection through at least April 20, 2015, according to the company. The court also ruled generic versions would infringe ’528 patent claims and issued a permanent injunction barring companies from marketing the generics until at least April 20, 2015.
Generic Line
Generic Line
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May